{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:42:48Z","timestamp":1792212168602,"version":"4.4.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.2169\/internalmedicine.6976-25","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:38Z","timestamp":1771884578000},"page":"2758-2762","source":"Crossref","is-referenced-by-count":1,"title":["Embolic Ischemic Stroke Associated with Maintenance Intravenous Immunoglobulin Therapy"],"prefix":"10.2169","volume":"65","author":[{"given":"Ryoji","family":"Miyano","sequence":"first","affiliation":[{"name":"Department of Neurology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sakiyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 29: 491-498, 2017.","DOI":"10.1093\/intimm\/dxx039"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 122: 1238-1239, 2008.","DOI":"10.1016\/j.jaci.2008.08.033"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jiang M, Kimber JS, Gupta A, et al. Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review. Int Arch Allergy Immunol 184: 513-528, 2023.","DOI":"10.1159\/000529110"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ammann EM, Jones MP, Link BK, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127: 200-207, 2016.","DOI":"10.1182\/blood-2015-05-647552"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44: 223-226, 1994.","DOI":"10.1212\/WNL.44.2.223"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov 3: 141-144, 2008.","DOI":"10.2174\/157489008784705359"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339: 662-664, 1992.","DOI":"10.1016\/0140-6736(92)90806-E"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ben-Ami R, Barshtein G, Mardi T, et al. A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. Am J Physiol Heart Circ Physiol 285: H2663-H2669, 2003.","DOI":"10.1152\/ajpheart.00128.2003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 65: 30-34, 2000.","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 41: 153-158, 1999.","DOI":"10.1159\/000008040"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90: 981-987, 2019.","DOI":"10.1136\/jnnp-2019-320314"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Van den Bergh PYK, van Doorn PA, Had den RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force - Second revision. Eur J Neurol 28: 3556-3583, 2021.","DOI":"10.1111\/ene.14959"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 18: 784-794, 2019.","DOI":"10.1016\/S1474-4422(19)30144-9"},{"key":"14","unstructured":"14. Allen JA, Lin J, Basta I, et al.  Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 23: 1013-1024, 2024."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306, 2006.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"16","unstructured":"16. Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol  75: 1687-1702, 2023."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Elgendy AY, Saver JL, Amin Z, et al. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke. JAMA Neurol 77: 878-886, 2020.","DOI":"10.1001\/jamaneurol.2020.0458"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH. Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol 78: 216-220, 2005.","DOI":"10.1002\/ajh.20287"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kuwabara S, Mori M, Misawa S, et al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88: 832-838, 2017.","DOI":"10.1136\/jnnp-2017-316427"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Labeyrie C, Cauquil C, Sarov M, Adams D, Denier C. Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 54: 166-167, 2016.","DOI":"10.1002\/mus.25076"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. Ann Pharmacother 49: 715-726, 2015.","DOI":"10.1177\/1060028015576362"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60: 1822-1824, 2003.","DOI":"10.1212\/01.WNL.0000068335.01620.9D"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6976-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:16:38Z","timestamp":1792210598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6976-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":22,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6976-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"6976-25"}}